Epithelioid
Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience
Thoracic Cancer 2022 September 2 [Link] Francesco Falanga, Pietro Rinaldi, Cristiano Primiceri, Chandra Bortolotto, Olga Oneta, Francesco Agustoni, Patrizia Morbini, Laura Saracino, Dimitrios Eleftheriou, Federico Sottotetti, Giulia Maria Stella Abstract Surgery is part of a multimodal therapeutic approach to malignant pleural mesothelioma (MPM) although its real beneficial effect is still controversial. The optimal precise sequence…
Read MorePSO-Based Evolutionary Approach to Optimize Head and Neck Biomedical Image to Detect Mesothelioma Cancer
Biomed Research International 2022 August 5 [Link] Sheeba Praveen, Neha Tyagi, Bhagwant Singh, Girija Rani Karetla, Meenakshi Anurag Thalor, Kapil Joshi, Melkamu Tsegaye Abstract Mesothelioma is a form of cancer that is aggressive and fatal. It is a thin layer of tissue that covers the majority of the patient’s internal organs. The treatments are available;…
Read MoreHypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases
Histopathology 2022 August 25 [Link] Andrew Churg, Julia R Naso Abstract Separation of mesothelioma from metastatic carcinoma requires immunohistochemical support, with small batteries of stains recommended as a starting-point, but these numbers commonly expand to 10, 12 or more stains, a process that is not only expensive but frequently generates anomalous or confounding results, leading…
Read MoreFDG PET/CT for Staging and Restaging Malignant Mesothelioma
Seminars in Nuclear Medicine 2022 August 11 [Link] Egesta Lopci, Angelo Castello, Luigi Mansi Abstract Malignant mesothelioma is an aggressive tumor originating from the mesothelial cells and presenting in general with a very poor prognosis. The pleural localization represents the prevailing disease site, while peritoneal involvement is commonly rare. The WHO classifies mesotheliomas into epithelioid,…
Read MoreDiagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma
Journal of the American Society of Cytopathology 2022 July 9 [Link] Louise Andersen Lynggård, Vasiliki Panou, Weronika Szejniuk, Oluf Dimitri Røe, Christos Meristoudis Abstract Introduction: Serous effusion is often the first sign of mesothelioma. Diagnosis based on cytologic material from the effusions remains controversial and complementary biopsy is usually required. However, obtaining representative tissue sample…
Read MoreCurcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies
Frontiers in Oncology 2022 July 8 [Link] Daniel L Pouliquen, Alice Boissard, Cécile Henry, Olivier Coqueret, Catherine Guette Abstract Curcuminoids, which include natural acyclic diarylheptanoids and the synthetic analogs of curcumin, have considerable potential for fighting against all the characteristics of invasive cancers. The epithelial-to-mesenchymal transition (EMT) is a fundamental process for embryonic morphogenesis, however,…
Read MoreDoes mediastinal lymph node involvement influence the surgical outcome in malign pleural mesothelioma?
Acta Chirurgica Belgica 2022 July 15 [Link] Mehmet Ali Bedirhan, Yunus Seyrek, Volkan Yaran, Celal Buğra Sezen, Levent Cansever, Muzaffer Metin Abstract Background: This study examined the effect of metastatic mediastinal lymph node involvement on the prognosis of patients with malignant pleural mesothelioma (MPM) who underwent extrapleural pneumonectomy (EPP) or extended pleurectomy (E/P) and also…
Read MorePrognostic Role of Tumor Immune Microenvironment in Pleural Epithelioid Mesothelioma
Frontiers in Oncology 2022 June 20 [Link] Hely Ollila, Mikko I Mäyränpää, Lassi Paavolainen, Juuso Paajanen, Katja Välimäki, Eva Sutinen, Henrik Wolff, Jari Räsänen, Olli Kallioniemi, Marjukka Myllärniemi, Ilkka Ilonen, Teijo Pellinen Abstract Background: Pleural mesothelioma (MPM) is an aggressive malignancy with an average patient survival of only 10 months. Interestingly, about 5%-10% of the…
Read MoreThrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report
JTO Clinical and Research Reports 2022 June 9 [Link] Takaaki Tanaka, Shoji Asakura, Kazuya Hisamatsu, Nobukazu Fujimoto Abstract A 69-year-old man presented with a pulmonary opacity at a regular medical check-up. He had been exposed to asbestos in a chemical fiber manufacturing setting. Result of positron emission tomography with computed tomography (CT) revealed fluorodeoxyglucose accumulations…
Read MorePrognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients
World Journal of Surgical Oncology 2022 June 29 [Link]Jianting Ma, Shengzhi Zhang Abstract Background: Prognosis in malignant peritoneal mesothelioma (MPM) remains poor, and the associated factors are unclear. Therefore, this study aimed to investigate the prognostic factors of MPM. Methods: A total of 52 female MPM patients treated in 2012-2017 were retrospectively analyzed. Kaplan-Meier survival…
Read More